Fresh capital signals growing belief in preventive longevity care built for longer, healthier lives among the Indian population.
When an investor returns for a second round, it usually means something important has shifted – from promise to proof. That’s the story unfolding at Biopeak, India’s first longevity and health optimization brand, which has raised $2.7 million in a follow-on funding round led by NKSquared, the investment vehicle of Zerodha cofounder Nikhil Kamath [1].
Kamath first invested $1.43 million in Biopeak in August 2024. This latest round suggests that, over the past year, the company has done more than ride the global buzz around longevity; it has shown that its model can attract clients, deliver outcomes and begin scaling in a market not traditionally built for preventive care.
India’s healthcare system is strong at treating emergencies. It is far less organized around what happens before the emergency ever arrives. Many people move through years of subtle decline – poor sleep, metabolic strain, chronic stress – without a clear clinical framework to connect the dots.
Biopeak is trying to build that missing framework. Instead of asking, “What’s wrong today?”, the model asks, “Where is this person heading over the next 10 or 20 years?”. That shift, from episodic care to longitudinal care, is at the core of its approach.
“In India, we’re seeing a real shift in how people think about health, not just when something goes wrong, but how they stay well over time,” said Rishi Pardal, co-founder and CEO of Biopeak. “What’s been missing is a clinical system that connects diagnostics, specialists, and follow-up into one long-term view of health [1].”
At first glance, Biopeak’s model can sound technical: advanced diagnostics, AI-driven insights, multidisciplinary teams. But the underlying idea is intuitive. Think of it as building a detailed health map, then checking it regularly instead of once every few years.
The company’s proprietary Longevity Hexacode system combines deep testing with clinician expertise and AI-supported analysis [2]. The role of AI here is not to replace doctors, but to help spot patterns that humans might miss when reviewing years of data. Clinicians then translate those insights into practical, evolving care plans.
Rather than static advice, clients receive what Biopeak calls a “personal blueprint,” a living plan that adapts as their biology, habits and life circumstances change. The goal is not optimization for its own sake, but sustained healthspan: more years lived with energy, clarity and resilience.
Over the past year, Biopeak has expanded its clinical programs and grown its client base, particularly among high achievers, executives and women – groups often underserved by fragmented care pathways. The company has also opened a flagship clinic in Bengaluru and is preparing to launch another.
Pardal noted that they’ve already proven they can win over clients and perform well, but explained that more capital is needed to further validate their market fit and scale the business. That validation matters in a longevity sector sometimes criticized for hype. Investors are becoming more selective, favoring models rooted in clinical rigor rather than quick fixes or consumer wellness trends. Kamath’s continued backing reflects confidence that Biopeak is building infrastructure, not just offering services.
India’s longevity market is still early, but the forces shaping it are clear. Life expectancy has crossed 72 years, yet healthy life expectancy has not kept pace. More people are living longer, but often with reduced quality of life in later years. As awareness grows, so does demand for preventive and structured care.
Biopeak plans to use the new capital to expand diagnostics, research, proprietary AI and clinical program development, while hiring across clinical, product and operations teams. It is also strengthening ties with global advisors to reinforce protocol development and clinical governance.
This measured approach is notable. Scaling longevity care too quickly risks undermining trust; scaling it too slowly risks missing the moment. Biopeak appears to be threading that needle by prioritizing systems, evidence and continuity.
In that sense, the repeat investment is about more than one company. It reflects a broader realization taking hold among founders and investors alike: longevity is not a luxury add-on to healthcare. It is the long game and it requires building systems designed to last as long as we hope to.
Photograph courtesy of Biopeak
[1] https://www.tribuneindia.com/news/business/biopeak-attracts-repeat-investment-from-nikhil-kamath-to-scale-longevity-care/
[2] https://biopeak.com/our-solutions
